bold = Main text
Part, Chapter, Paragraphgrey = Comment text
1 II, 5. 9. 4 | wheeze (1.34 to 0.98:1 P <0.0002), asthma (1.74 to 1.02:1
2 III, 10. 2. 1 | 083 , 22/03/2006 P. 0014 – 0015.~[http://eur-lex.europa.
3 III, 10. 2. 1 | Journal L 052 , 22/02/2001 P. 0019 – 0025.~http://eur-lex.europa.
4 III, 10. 2. 1 | Journal L 109 , 06/05/2000 P. 0029 – 0042 [http://eur-lex.europa.
5 III, 10. 2. 1 | do?uri=OJ:L:2007:273:0001:0030:EN:PDF]~ ~European Council (
6 III, 10. 2. 1 | 404 , 30/12/2006 P. 0026 – 0038.~[http://eur-lex.europa.
7 III, 10. 2. 1 | 109 , 06/05/2000 P. 0029 – 0042 [http://eur-lex.europa.eu/
8 III, 10. 2. 1 | Journal L 183 , 12/07/2002 P. 0051 – 0057.~[http://eur-lex.
9 III, 10. 2. 1 | 183 , 12/07/2002 P. 0051 – 0057.~[http://eur-lex.europa.
10 IV, 13. 2. 2 | 616 544 for males, and 579 006 for females, respectively.
11 II, 5. 9. 4 | nursing (2.2, 1.3-4.0, P=0.007). Asthma risk was also increased
12 II, 5. 9. 4 | symptoms (2.4, 1.3-4.6, P=0.008). Among common occupations,
13 II, 9. 3. 1 | 263; doi:10.1136/sti.2004.009415~ ~Forsgren L, Beghi E, Õun
14 III, 10. 2. 1 | 04_scenihr/docs/scenihr_o_013.pdf~ ~European Network for
15 II, 5. 5. 3 | the incidence rate is 0.016 to 0.042% with a broad variation
16 II, 5. 5. 3 | value reported for Norway (0.0164). On the other hand, data
17 IV, 13. 2. 3 | acrylamide~ ~ ~ ~<300~ ~STEC 0175 (5)~PAHs (5) other substances~ ~
18 II, 4. 2 | regression coefficient equals -.020, which implies that if life
19 III, 10. 4. 3 | International Lakes. EUR/ICP/EHCO 020205/8Fin, 18 October 1999. Available
20 II, 5. 2. 7 | 10.1016/j.ypmed.2008.01.023] (accessed on 17 March 2008).~
21 II, 9. 5. 4 | screening guidelines (COM (2003) 0230, Proposal for a Council
22 II, 4. 2 | regression coefficient equals -.024, implying that convergence
23 II, 5. 8. 5 | of 10+ pack-years (n=11,027). After a minimal antismoking
24 II, 5. 11. 3 | NMSC (19 600 in men and 19 029 in women). During this period,
25 III, 10. 4. 2 | were found in trouts: 0.02µg/g fish based on a TDI (Tolerable
26 III, 10. 4. 2 | 2005.pp. 156. ISBN: 92-9199-030-2.~ ~EFSA (2005): Summary
27 III, 10. 2. 1 | subjects (22,924 women and 13,031 men) who participated in
28 II, 7. 7 | a safer Europe. COM/2006/0328 of June 23, 2006 (CELEX-Nr.
29 II, 4. 2 | regression coefficient equals -.034, implying that convergence
30 II, 9. 3. 3 | C 271 E , 12/11/2003 P. 0369 - 0374~Facultes Universitaires
31 II, 9. 3. 3 | E , 12/11/2003 P. 0369 - 0374~Facultes Universitaires
32 II, 5. 5. 3 | incidence rate is 0.016 to 0.042% with a broad variation
33 III, 10. 4. 2 | European Communities No. L 043, 14 February 1997. Available
34 II, 6. 3. 3 | Risk factors~ ~In 2005, 28 044 HIV diagnoses were reported
35 II, 5. 9. 4 | 1989 (n=3,390), 1994 (n=4,047), 1999 (n=3,540) and 2004 (
36 IV, 11. 1. 5 | score for each practice of 1,050 points, with scores of individual
37 III, 10. 2. 1 | healthpromotion/conferences/6gchp/hpr_050829_%20BCHP.pdf].~ ~World Health
38 II, 5. 9. 4 | 3, 95% CI 1.0-11.1, P=0.051). The population-attributable
39 III, 10. 2. 1 | relevance):~Official Journal L 052 , 22/02/2001 P. 0019 – 0025.~
40 II, 5. 2. 6 | meta-analysis of data from 90,056 participants in 14 randomised
41 III, 10. 3. 2 | sensitisation can be as low as 0.05μg/m3 air for previously sensitised
42 III, 10. 6. 2 | socio_economics/documents/ev_060302_rd06_en.pdf].~ ~ ~ ~
43 III, 10. 4. 2 | pp. 157~ISBN: 978-92-9199-064-1~ ~EFSA (2006c): Summary
44 II, 5. 3. 6 | European countries on 2 699 086 adult cancer cases that
45 II, 6. 3. 4 | SARS-CoV had resulted in 8 098 SARS cases in 26 countries,
46 IV, 12. 10 | residues regulations~S.I. 910 0f 2005 - food & feed hygiene
47 II, 5. 5. 3 | from 4 per 10,000 to 66 per 10000 children in the last 20
48 II, 5. 6. 6 | fractures. Am.J Epidemiol 137:1001-1005~Cooper C, Melton LJ,
49 II, 5. 7. 3 | 1209 pmp) and in Canadians (1003 pmp) (U.S. Renal Data System,
50 II, 5. 5. 3 | epilepsy. Neurology 63:1002-1007.~Sidenvall R, Forsgren L,
51 III, 10. 2. 1 | Clinical Nutrition 58, 1000-1010~Greece~Data not available~ ~ ~ ~ ~
52 II, 5. 5. 3 | in Estonia. Epilepsia 40:1011-1019.~Berg AT, Shinnar S (
53 II, 5. 8. 7 | Eur Respir J 2007; 30: 993–1013~ ~Vrbica Ž (2007): COPD
54 II, 5. 7. 7 | Intern Med 2007 Jul;22(7):1018-23.~Smith DH, Gullion CM,
55 II, 5. 5. 3 | Estonia. Epilepsia 40:1011-1019.~Berg AT, Shinnar S (1991):
56 II, 5. 6. 6 | diseases. J Rheumatol 19:1020-1030~Sernbo I, Johnell O (
57 III, 10. 5. 1 | Abnormal Child Psychology 35(6):1021-33.~Brenner BL et al, (2003):
58 II, 5. 5. 3 | InterScience DOI: 10.1002/eat.1022.~Levey R (2006): Anorexia
59 III, 10. 5. 1 | In: Ann. N.Y. Acad. Sci. 1023: 308-322 (2004).~Em M (1998):
60 II, 5. 5. 3 | epileptic seizure. Epilepsia 42:1025-1030.~Loiseau J, Loiseau
61 II, 5. 2. 7 | life. Arch Intern Med 165:1028-34.~EUROCISS Project Research
62 II, 5. 5. 3 | really exist? J Neurol 246:1033–1040.~Ford HL, Gerry E,
63 III, 10. 2. 1 | Related Metabolic Disorders 26:1036-1045.~ ~Savva SC, Tornaritis
64 III, 10. 2. 4 | online 1 April 2008; doi:10.1038/nrg2360: 2-7.~ ~Roberts,
65 II, 5. 6. 6 | Association. Arthritis Rheum 29:1039-1049~Anderson JA (1986)
66 II, 5. 5. 3 | exist? J Neurol 246:1033–1040.~Ford HL, Gerry E, Airey
67 III, 10. 2. 5 | Psychol Psychiatry 2007;48:1042-50.~ ~Mäntymaa M, Puura
68 III, 10. 2. 1 | Metabolic Disorders 26:1036-1045.~ ~Savva SC, Tornaritis
69 II, 5. 6. 6 | Arthritis Rheum 29:1039-1049~Anderson JA (1986) Epidemiological
70 IV, 12. 10 | system (resolution number 105136/GG 907B/17-06-04) for the
71 II, 5. 9. 7 | Questionnaire survey. BMJ 2004; 328:1052-1053.~ ~Baiardini I, Braido
72 II, 5. 9. 7 | survey. BMJ 2004; 328:1052-1053.~ ~Baiardini I, Braido F,
73 II, 5. 5. 3 | study. Mult Scler 13(8):1054-64. Erratum in: Mult Scler.
74 II, 5. 15. 6 | Pediatrics, 1978;62(6):1056-1060.~Kesselman I, Elstein
75 II, 5. 7. 3 | patients pmp in Romania to 1057 patients pmp in Germany (
76 II, 5. 5. 3 | categories. Epilepsia 37:1051-1059.~Pazzaglia P, Frank-Pazzaglia
77 IV, 11. 6. 5 | Assessment in Health Care 16(4): 1061-76.~ ~Rizzo J, Blumenthal
78 II, 5. 5. 3 | for epilepsy. Epilepsia 38:1062-1068.~Nilsson L, Ahlbom
79 II, 5. 5. 3 | epilepsy. Epilepsia 38:1062-1068.~Nilsson L, Ahlbom A, Farahmand
80 II, 5. 9. 7 | Committee. Eur Respir J 2002; 20:1071-1079~ ~Fasce L, Tosca MA,
81 II, 5. 9. 7 | Eur Respir J 2002; 20:1071-1079~ ~Fasce L, Tosca MA, Silvestri
82 II, 5. 5. 3 | study. Epilepsia 43:1076-1083.~Beghi E (2004): Aetiology
83 II, 5. 5. 3 | clinical trial. The Lancet 371: 1085-1097.~Klosterkötter J (2007):
84 III, 10. 1. 3 | Sports Exerc 29(8):1076-1089.~Kuntsche E, Jordan MD (
85 II, 5. 3. 5 | by sex A) Men~Figure 5.3.10b. Trends of colorectal cancer (
86 IV, 12. 10 | May;~Portaria nb 174/97 of 10March~Despacho nb 242/96 of 13
87 II, 5. 9. 7 | Respir.Sep; 23 (4 Pt 2):10S73-10S75~ ~Bousquet PJ, Hooper R,
88 III, 10. 4. 2 | in food amounts~to about 10x that of~benzo(a)pyrene~EU
89 II, 5. 5. 3 | not, was 72%, while the 10y survival rate was 42% and
90 II, 5. 5. 3 | has been implementing a 10yr ‘ASD Strategic Action Plan
91 II, 5. 8. 7 | population. Chest 2004; 126; 1093-1101.~ ~V . (2007): Definition,
92 III, 10. 2. 1 | comparison. BMJ, 2000; 320(7242): 1102-1107.~ ~CDC (2004): 2004
93 III, 10. 1. 3 | filebank/files/20080109$110739$fil$mZ8UVQv2wQFShMRF6cuT.
94 II, 5. 5. 3 | and incident cohort~4001~1109.0~3.6~Nilsson et al, 1997~
95 III, 10. 2. 1 | Related Metabolic Disorders 24:1111–1118.~ ~Novakova J (2006):
96 II, 5. 10. 7 | Toxicol. 2007 Jul;45(7):1116-22. Epub 2007 Jan 9.~ ~Woods
97 III, 10. 2. 1 | Metabolic Disorders 24:1111–1118.~ ~Novakova J (2006): Antropometrické
98 II, 5. 11. 7 | population. Cancer 2000;89:1121–1133.~ ~De Vries E, Bray
99 II, 5. 5. 3 | Arch Gen Psychiatry 64(10):1123-31.~Sartorius N (2007):
100 III, 10. 3. 2 | Environm. Hlth. Perspec. 113, 1125-1133.~ ~Bundesinstitut für
101 II, 5. 8. 7 | rural men. Chest 2006; 130: 1129-1137.~ ~Rea H, McAuley S,
102 II, 5. 12. 7 | Multi-centre group. J Hepatol 30:1130-1137.~ ~Ramstedt M (2001):
103 II, 5. 11. 7 | advantaged? Br Med J 1994;308:1132-35.~ ~Williams HC, Burney
104 II, 5. 6. 6 | organization. Arthritis Rheum 38:1134-1141~Ollier WE, Harrison
105 II, 9. 3. 1 | Inf. 80;255-263; doi:10.1136/sti.2004.009415~ ~Forsgren
106 III, 10. 2. 1 | Public Health Nutrition 10:1138-1144.~ ~Ministry of Health
107 II, 5. 10. 7 | admissions data. BMJ 327:1142-1143~International Life
108 II, 5. 10. 7 | admissions data. BMJ 327:1142-1143~International Life Sciences
109 III, 10. 2. 1 | Health Nutrition 10:1138-1144.~ ~Ministry of Health and
110 IV, 11. 6. 5 | Science and Medicine 53: 1149-1162.~ ~Goldfarb NI, Maio
111 III, 10. 2. 1 | British Medical Journal 308:1153–1156.~ ~Pudule I, Jēce I,
112 III, 10. 2. 1 | Medical Journal 308:1153–1156.~ ~Pudule I, Jēce I, Velika
113 II, 5. 2. 6 | Study). J Hypertens 14: 1159-1166.~Lewington S, Whitlock
114 IV, 11. 6. 5 | Science and Medicine 53: 1149-1162.~ ~Goldfarb NI, Maio V et
115 II, 5. 8. 7 | Burden of Airway Disease. 10.1164/ rccm.167.5.787. Am.J.Resp.
116 II, 5. 2. 6 | Study). J Hypertens 14: 1159-1166.~Lewington S, Whitlock G,
117 II, 5. 5. 3 | disease. Eur J Neurol 13(11):1170-1185.~Hughes AJ, Daniel
118 III, 10. 2. 1 | of Clinical Nutrition 60:1174-1179.~ ~Grabauskas V, Klumbienė
119 III, 10. 5. 1 | environment. Lancet 29;370(9593): 1175-87~ ~Wright AJ, et al (2005):
120 III, 10. 2. 1 | COUNCIL REGULATION (EC): No 1182/2007 of 26 September 2007
121 III, 10. 2. 1 | Nutr., 2001, 4, 5(B), p. 1183-1186~Portugal~Data not available~ ~ ~ ~ ~
122 III, 10. 5. 1 | Lancet. 2002 Oct 19;360(9341):1184-5.~Daisey JM, Angell WJ
123 II, 5. 5. 3 | Eur J Neurol 13(11):1170-1185.~Hughes AJ, Daniel SE, Kilford
124 II, 5. 5. 3 | difficulty. Epilepsia 36:1187-1194.~Nashef L, Walker F,
125 II, 5. 6. 6 | Assess Health Care 16(4):1193-200~Juni P, Dieppe P, Donovan
126 II, 5. 5. 3 | difficulty. Epilepsia 36:1187-1194.~Nashef L, Walker F, Allen
127 III, 10. 2. 1 | Health Nutr 5 (6B), 1179-1196.~ ~ ~EFCOSUM Group (2002):
128 II, 5. 3. 5 | sex B) Women~ ~Figure 5.3.11a. Colorectal cancer (ICD9
129 II, 5. 3. 5 | in 2006 A) Men~Figure 5.3.11b. Colorectal cancer (ICD9
130 III, 10. 3. 1 | dwellings leads to 100 to 1200 extra cases of lung cancer
131 III, 10. 4. 2 | Health Perspectives 112(12): 1204-1207~ ~Kallenborn, R. and
132 II, 8. 2. 1 | carried out in a cohort of 12058 children followed up to
133 II, 5. 7. 3 | than that in US whites (1209 pmp) and in Canadians (1003
134 III, 10. 2. 1 | Sweden~RIKSMATEN~1997-1998~1210~17-79~Individual dietary
135 II, 9. 3. 3 | subsequent condom use. Aids 19:1215-23.~Layte R, McGee H, Qual
136 III, 10. 2. 5 | behavior. Child Dev 2007;78:1222-39.~ ~Barker DJP, Osmond
137 III, 10. 2. 1 | Health Nutr 5 (6B), 1217-1226.~ ~Linseisen J, Bergstrom
138 III, 10. 2. 1 | Health Nutr 2002 Dec, 5 (6B): 1227-1242.~ ~Linseisen J, Kesse
139 II, 5. 2. 7 | Europe. Eur Heart J 18: 1231–48.~Sarti C, Stegmayr B,
140 II, 5. 9. 7 | Immunol. 2003 Jun;111(6):1232-8~ ~von Mutius (2006): The
141 II, 5. 5. 3 | MR review and examination~1233 ~6.3 ~Keranen et al., 1989 (*)~
142 II, 5. 5. 3 | Environ Health Perspect 113(9):1234-1238.~McCrone P, Allcock
143 II, 9. 3. 1 | and Health, Finland, ISSN 1236-2050, 2007:2) ISBN 978-952-
144 III, 10. 2. 1 | British Medical Journal 320:1240–1243.~ ~Currie C, Roberts
145 III, 10. 2. 1 | Nutr 2002 Dec, 5 (6B): 1227-1242.~ ~Linseisen J, Kesse E,
146 III, 10. 2. 4 | tumors. Am J Pathol, 158:1245-1251.~ ~Ibarreta D, Bock, A.K.,
147 III, 10. 5. 1 | schoolwork by children (1257-RP).~ ~Walinder R, Gunnarsson
148 III, 10. 2. 1 | Nutr 2002 Dec, 5 (6B):1243-1258.~ ~Linseisen J, Rohrmann
149 II, 5. 10. 7 | allergen labelling? Allergy 59:1262-8.~ ~Mills ENC, Mackie AR,
150 II, 5. 5. 3 | childhood. Pediatrics 107:1259-1263.~Cockerell OC, Eckle I,
151 II, 5. 2. 6 | of statins. Lancet 366: 1267-1278.~Lewington S, Clarke
152 II, 5. 6. 6 | disease in farmers. BMJ 304:1269-1272~Cummings SR, Nevitt
153 II, 5. 4. 8 | Diabetes Care. 2003 Apr;26(4):1270-6.~Greenfield S, Nicolucci
154 II, 5. 6. 6 | in farmers. BMJ 304:1269-1272~Cummings SR, Nevitt MC,
155 III, 10. 2. 1 | Public Health Nutr 5 (6B): 1273-1285.~ ~ ~
156 II, 5. 5. 3 | in children. Epilepsia 38:1275-1282.~Fisher RS (2000):
157 II, 9. 4. 7 | Biol Sci Med Sci, (12), p.1277-84.~DECODE study group on
158 II, 5. 2. 6 | statins. Lancet 366: 1267-1278.~Lewington S, Clarke R,
159 II, 5. 5. 3 | children. Epilepsia 38:1275-1282.~Fisher RS (2000): Epilepsy
160 III, 10. 2. 1 | Health Nutr 5 (6B): 1273-1285.~ ~ ~
161 III, 10. 2. 1 | Health Nutr 2002 Dec, 5 (6B): 1287-1296.~ ~Welch AA, Lund E,
162 II, 5. 2. 6 | disease. N Engl J Med 345: 1291-1297.~ ~
163 II, 5. 2. 6 | N Engl J Med 345: 1291-1297.~ ~
164 IV, 12. 10 | health~ high~o The direction 1299/2003 of the Ministry of
165 II, 5. 3. 5 | by sex A) Men~Figure 5.3.12b. Trends of colorectal cancer (
166 II, 5. 6. 6 | quality of life. Am J Med 103:12S-17S~Cooper C, Atkinson EJ, Jacobsen
167 III, 10. 2. 1 | starting on average just after 12½ years of age. Data from
168 II, 5. 7. 7 | Soc Nephrol 2004 May;15(5):1300-6.~Stengel B, Billon S,
169 I, 2. 4. 0(1) | PREREL_YEAR_2009_MONTH_02/2-13022009-EN-AP.PDF]~
170 III, 10. 3. 1 | Reference: ISO/TC 43/SC 1 N 1313.~Kempen EEMM van, Kruize
171 III, 10. 2. 1 | Australia. Addiction, 99: 1315-1322.~ ~European Monitoring
172 III, 10. 2. 1 | Australia. Addiction, 99: 1315-1322.~ ~European Monitoring Centre
173 II, 5. 4. 8 | Acad Sci U S A. 14;104(33):13225-31~TRIG p (2007): Study
174 II, 5. 6. 6 | population. Arthritis Rheum 33:1323-1332~Kanis JA, Johnell O,
175 IV, 12. 10 | Gender issues~ high~o Law 1329/1983: Modernization of the
176 II, 5. 6. 6 | Arthritis Rheum 33:1323-1332~Kanis JA, Johnell O, Oden
177 II, 5. 10. 7 | research: a review. Allergy 61,1336-1343.~ ~European Commission (
178 IV, 12. 10 | 2006 a Screening Decree (1339/2006) which took effect
179 II, 5. 10. 7 | review. Allergy 61,1336-1343.~ ~European Commission (
180 II, 5. 8. 7 | COPD. Respir Med 2006; 100: 1349-1355.~ ~Viegi G, Pedreschi
181 II, 5. 8. 7 | Respir Med 2006; 100: 1349-1355.~ ~Viegi G, Pedreschi M,
182 II, 5. 5. 3 | on Aging. Neurology 55(9):1358-1363.~Benito-Leon J, Bermejo-Pareja
183 IV, 12. 10 | o Ministerial Decision 13588/725/2006 “Measures, terms
184 II, 5. 5. 3 | Aging. Neurology 55(9):1358-1363.~Benito-Leon J, Bermejo-Pareja
185 III, 10. 2. 1 | Icelanders 2002~DOI~2002~1366~15-80~24-hour recall~1~The
186 II, 5. 6. 6 | population study. J Rheumatol 28:1369-1377~Birnbaum HG, Barton,
187 II, 5. 8. 7 | finding study. BMJ 2002; 324: 1370-1374.~ ~Vermeeren MA, Creutzberg
188 II, 5. 8. 7 | study. BMJ 2002; 324: 1370-1374.~ ~Vermeeren MA, Creutzberg
189 II, 5. 6. 6 | study. J Rheumatol 28:1369-1377~Birnbaum HG, Barton, M,
190 II, 5. 4. 3 | ranging between 10 (Italy) and 1380 (Slovak Republic).~The annual
191 II, 5. 6. 6 | fractures. J Bone Miner Res 15:1384-1392~Oliveria SA, Felson
192 II, 5. 5. 3 | population-based study. Epilepsia 40:1388-1392.~Massey EW, Schoenberg
193 III, 10. 5. 1 | Number 11, November 1998, pp. 1389-1396(8)~ ~European Child
194 III, 10. 5. 1 | November 1998, pp. 1389-1396(8)~ ~European Child Safety
195 II, 5. 3. 5 | in 2006 A) Men~Figure 5.3.13b. Lung cancer (ICD9 162)
196 II, 8. 2. 1 | Journal of Public Health 13S: 101-6.~Lennox N, Beange
197 III, 10. 4. 2 | showed an average intake of 0.13µg/kg bw (EFSA, 2006).~ ~PFOS
198 IV, 12. 10 | Environment Management System ISO 14000 / ISO 14001. ~ ~Use of pesticides~
199 IV, 12. 10 | Management System ISO 14000 / ISO 14001. ~ ~Use of pesticides~ high~ ~ ~
200 II, 5. 5. 3 | unprovoked seizures. Epilepsia 43:1402-1409.~Lindsten H, Nystrom
201 II, 5. 5. 1 | EQ-5D. Qual Life Res 15(8):1403-14.~ ~Schmidtke A., Bille-Brahe
202 II, 5. 5. 3 | for stigma. Epilepsia 45:1405-1415.~Jallon P (2004): Mortality
203 IV, 12. 1 | Social security~Regulation 1408/71 Providing for the payment~(
204 II, 5. 5. 3 | seizures. Epilepsia 43:1402-1409.~Lindsten H, Nystrom L,
205 II, 5. 5. 3 | stigma. Epilepsia 45:1405-1415.~Jallon P (2004): Mortality
206 III, 10. 2. 4 | 16p12.2. Diabetologia, 50:1418-1422.~ ~Hoos A, Urist MJ,
207 III, 10. 2. 4 | 2. Diabetologia, 50:1418-1422.~ ~Hoos A, Urist MJ, Stojadinovic
208 II, 5. 5. 3 | sclerosis. N Engl J Med 343:1430–1438.~Confavreux C, Vukusic
209 III, 10. 2. 1 | Obstetrics and Gynaecology 112:1431–1433.~ ~Kapantais E, Haralambides
210 II, 5. 6. 6 | ability. J Rheumatol 21:1432-1437~Hochberg MC, Chang
211 III, 10. 2. 1 | and Gynaecology 112:1431–1433.~ ~Kapantais E, Haralambides
212 II, 5. 6. 6 | ability. J Rheumatol 21:1432-1437~Hochberg MC, Chang RW, Dwosh
213 II, 5. 5. 3 | smoking and alcohol use in 144 PD patients and 464 matched
214 III, 10. 6. 1 | of Public Health 93(9): 1442-1445.~ ~Currie C, Gabhainn
215 II, 5. 5. 3 | scale (EDSS). Neurology 33:1444-1452.~Larocca et al. Factors
216 II, 5. 11. 3 | New York:McGraw-Hill, 1999:1447-1461.~Boc A. A pilot study
217 II, 5. 9. 4 | environmental factors among 1450 children aged 13- to 14-
218 III, 10. 5. 1 | Journal of Public Health 93(9):1451-1456.~Kim HS, Mccarthy H,
219 II, 5. 11. 3 | York:McGraw-Hill, 1999:1447-1461.~Boc A. A pilot study on
220 III, 10. 2. 1 | adults. Obesity Research 12:1464–1472.~ ~Boros J, Németh
221 III, 10. 2. 1 | CD004148. DOI: 10.1002/14651858.CD004148.pub3.~ ~Olsson
222 II, 5. 5. 3 | population-based study. Epilepsia 41:1469-1473.~Lhatoo SD, Sander
223 II, 5. 5. 3 | study. Epilepsia 41:1469-1473.~Lhatoo SD, Sander JWAS,
224 II, 5. 8. 7 | Disease Study. Lancet 349: 1498–1504.~ ~Murtagh E, Heaney
225 II, 9. 1. 1 | group of children born 1000-1499g (Platt et al, 2007).~ ~Table
226 II, 9. 1. 1 | a weight at birth below 1500g. VLBW rate among live births
227 II, 5. 8. 7 | Study. Lancet 349: 1498–1504.~ ~Murtagh E, Heaney L,
228 II, 5. 5. 3 | sclerosis. Update. Nervenarzt 77:1506-18. (Article in German)~
229 II, 5. 5.Int(21)| period 2002-2006, Decision N° 1513/2002/EC of the European
230 II, 9. 3. 1 | Cancer Inst, 1997. 89(20): p. 1516-23~ ~Makino M, Tsuboi K,
231 II, 5. 2. 6 | randomised trials. Lancet 362: 1527-1535.~Vasan RS, Larson MG,
232 II, 5. 2. 6 | trials. Lancet 362: 1527-1535.~Vasan RS, Larson MG, Leip
233 II, 8. 2. 1 | disabilities.~In a survey of 1542 adults with intellectual
234 II, 5. 2. 7 | cardiovascular disease. Lancet 353:1547-57.~Tunstall-Pedoe H, Vanuzzo
235 II, 5. 8. 7 | cohort. Chest 2005; 127: 1544-1552.~ ~Lindberg A, Eriksson
236 III, 10. 3. 1 | Technical Specification ISO/TS 15666 Acoustics – Assessment of
237 III, 10. 4. 2 | in 1999, to 823 in 2000, 1567 in 2001, 3024 in 2002, 4414
238 IV, 12. 10 | health issues~ high~o Law 1568/1985 “Health and Safety
239 II, 5. 5. 3 | Psychiatric Association 156th Annual Meeting: Abstract
240 II, 5. 2. 6 | and treatment. JAMA 275: 1571-1576.~Keys A, Aravanis C,
241 II, 5. 8. 7 | Respir. Crit. Care Med. 163:1572-1577.~ ~ ~
242 II, 5. 5. 3 | PEDIATRICS Vol. 114 No. 6, 1574-1583.~NEDA (National Eating
243 II, 5. 2. 6 | treatment. JAMA 275: 1571-1576.~Keys A, Aravanis C, Blackburn
244 II, 5. 6. 6 | of 10 years. BMJ 320:1577-1578~Petersson IF, Jacobsson
245 II, 5. 5. 3 | PEDIATRICS Vol. 114 No. 6, 1574-1583.~NEDA (National Eating Disorders
246 II, 5. 2. 7 | All-Cause Mortality JAMA 292:1588-1592.~Daviglus ML, Liu K,
247 IV, 11. 6. 5 | Services Research 39(5): 1589-606.~ ~Robinson R, Jakubowski
248 II, 5. 2. 7 | Mortality JAMA 292:1588-1592.~Daviglus ML, Liu K, Pirzada
249 II, 9. 5. 6 | Public Health, 4th ed, p 1596~ ~White AK, Holmes M (2006):
250 IV, 11. 6. 5 | Report 2000." Lancet 356: 1598-1601.~ ~Naylor CD, Iron
251 II, 5. 7. 5 | counties, the so called "§15a-Vereinbarung".~· In the Czech Republic,
252 II, 5. 3. 5 | in 2006 A) Men~Figure 5.3.15b. Lung cancer (ICD9 162)
253 II, 5. 5. 1 | survey in Finland using 15D and EQ-5D. Qual Life Res
254 IV, 11. 6. 5 | 2000." Lancet 356: 1598-1601.~ ~Naylor CD, Iron K et
255 II, 5. 5. 3 | J Neural Transm 112(12):1605-1612.~von Campenhausen S,
256 II, 5. 5. 3 | Neural Transm 112(12):1605-1612.~von Campenhausen S, Bornschein
257 I, 2. 5. 0(3) | PREREL_YEAR_2008_MONTH_12/2-16122008-EN-AP.PDF~
258 II, 5. 5. 3 | population. Epilepsia 45:1613-1622.~Gallitto G, Serra
259 III, 10. 1. 3 | consequences. Addiction 91(11):1615-1621.~Rosner B (2000): Fundamentals
260 III, 10. 2. 1 | Metabolic Disorders 26:1610-1616.~ ~Savva SC, Kourides Y,
261 III, 10. 2. 1 | http://lib.bioinfo.pl/pmid:16184880~Iceland~The Diet of Icelanders
262 III, 10. 5. 3 | European Heart Journal 27:1610-1619.~Martikainen, P. & Valkonen,
263 III, 10. 1. 3 | consequences. Addiction 91(11):1615-1621.~Rosner B (2000): Fundamentals
264 II, 5. 5. 3 | population. Epilepsia 45:1613-1622.~Gallitto G, Serra S, La
265 II, 9. 3. 1 | carcinoma. Cancer 104(8): 1633-1637~ ~Lim LS, Fitzpatrick
266 III, 10. 2. 1 | British Medical Journal, 316: 1636-42.~ ~Ljung R, Peterson
267 II, 9. 3. 1 | carcinoma. Cancer 104(8): 1633-1637~ ~Lim LS, Fitzpatrick RD (
268 III, 10. 2. 1 | Alimentaires~INCA~1998-1999~1642~15-92~Individual dietary
269 III, 10. 5. 1 | Health Perspectives, 111:1649–1653.~Cla W (2002): Effect
270 III, 10. 4. 3 | problem. Toxicology Letters 164S: S324-S325~Valent F, et
271 III, 10. 5. 1 | Health Perspectives, 111:1649–1653.~Cla W (2002): Effect of
272 IV, 12. 10 | substance abuse~ High~Decision 1654/11/2006 for approval of
273 II, 5. 11. 7 | publication No. (PHS) 79–1660. US Department of Health,
274 III, 10. 1. 3 | consequences. Addiction 91(11):1663-1674.~Brady KT, Sonne SC (
275 III, 10. 1. 3 | consequences. Addiction 91(11):1663-1674.~Brady KT, Sonne SC (1999):
276 II, 5. 5. 3 | Marino. Neurology 37(10):1679-1682.~de Rijk MC, Breteler
277 II, 5. 6. 6 | population. Am J Public Health 87:1680-1682~Reynolds DL, Chambers
278 II, 5. 8. 7 | disease? Chest 2003; 123: 1684-1692.~ ~Horton K (2008):
279 II, 5. 8. 7 | disease? Chest 2003; 123: 1684-1692.~ ~Horton K (2008): The
280 II, 5. 7. 7 | Soc Nephrol 2006 Jun;17(6):1695-702.~ERA-EDTA Registry (
281 IV, 11. 6. 5 | general practice." BMJ 300: 1698-701.~ ~Kutzin J (1998):
282 III, 10. 2. 4 | diabetes locus on chromosome 16p12.2. Diabetologia, 50:1418-
283 IV, 12. 10 | Way’ was launched on June 16th 2008.~ ~ ~B) Actions adopted
284 III, 10. 2. 1 | prevalence of cannabis among 15-16y-old students~ ~Drug use among
285 III, 10. 5. 1 | analyses of water samples from 1700 public and 3300 private
286 II, 5. 6. 6 | population survey. J Rheumatol 24:1703-1709~Hakala M, Nieminen
287 II, 5. 6. 6 | survey. J Rheumatol 24:1703-1709~Hakala M, Nieminen P, Koivisto
288 III, 10. 2. 4 | J Public Health, 86(12): 1717-1722.~ ~Kononen J, Bubendorf
289 III, 10. 2. 1 | Consumption Survey~BNFCS2004~2004~1723~16-64~24-hour recall~2~General
290 III, 10. 2. 1 | Nutrition Survey~NDNS~2000-2001~1724~19-64~Individual dietary
291 III, 10. 4. 1 | health, NO 10/2005. ISSN 1725-9177.~ ~Clean Air for Europe (
292 II, 5. 8. 7 | data. Lancet 2006; 367: 1747-1757.~ ~Lundback B, Lindberg
293 III, 10. 2. 1 | study~SISP04~2003 - 2004~1751~16-64~24-hour recall~2~General
294 II, 5. 8. 7 | Lancet 2006; 367: 1747-1757.~ ~Lundback B, Lindberg
295 IV, 12. 10 | public health law~Law 2006.1772 about water and aquatic
296 III, 10. 2. 1 | 2004]. Orvosi Hetilap 146:1781-1789 (in Hungarian).~ ~Rolland-Cachera
297 III, 10. 2. 1 | No 2826/2000, (EC): No 1782/2003 and (EC): No 318/2006
298 II, 9. 2. 7 | Council (2002): Decision No 1786/2002/EC adopting a programme
299 III, 10. 2. 1 | Orvosi Hetilap 146:1781-1789 (in Hungarian).~ ~Rolland-Cachera
300 II, 5. 5. 3 | for management. Lancet 359:1790-1791.~Rutter M, Graham P,
301 II, 5. 5. 3 | management. Lancet 359:1790-1791.~Rutter M, Graham P, Yule
302 II, 5. 14. 3 | GDP, or approximately 1/17th of overall health care expenditures.
303 III, 10. 5. 3 | top incidence rate of app. 1800 per 100,000 is reported
304 IV, 11. 1. 3 | systems dates back to the 1800s when Florence Nightingale
305 III, 10. 2. 5 | adults. N Engl J Med 2005;353:1802-909.~ ~Bastra L, Hadders-Algra
306 III, 10. 3. 1 | uv/health/solaruvradfull_180706.pdf)~Mcelroy Ja, Egan Km,
307 IV, 11. 6. 5 | methods." The Lancet 361: 1817-20.~ ~Navarro D (2000): "
308 II, 5. 7. 7 | Transplant 2003 Sep;18(9):1824-33.~Stevens PE, O'donoghue
309 II, 5. 5. 3 | Aeolian islands. Epilepsia 46:1828-1835.~Harris EC, Barraclough
310 II, 5. 2. 7 | case fatality?. Stroke 34:1833-1841~Thom TJ (1989): International
311 II, 5. 2. 6 | deaths. Lancet 370: 1829-1839.~Robinson JG, Smith B, Maheshwari
312 II, 5. 2. 7 | fatality?. Stroke 34:1833-1841~Thom TJ (1989): International
313 II, 9. 3. 3 | experience. Lancet 358(9296): 1843-1850.~Wellings K, Collumbien
314 II, 9. 3. 3 | pregnancy strategy: Lancet 368:1846-1848~ ~ ~
315 II, 9. 3. 3 | strategy: Lancet 368:1846-1848~ ~ ~
316 II, 5. 2. 6 | analysis. J Am Coll Cardiol 46: 1855-1862.~Stamler J, Wentworth
317 II, 5. 2. 6 | Am Coll Cardiol 46: 1855-1862.~Stamler J, Wentworth D,
318 III, 10. 5. 2 | British Journal of Cancer. 82, 1863-1866.~ ~Department of the
319 II, 9. 3. 3 | ethnic minorities. Aids 18 :1867-73.~Dubois-Arber F, Jeannin
320 II, 5. 5. 3 | in treated schizophrenia: 1875-1924 and 1994-1998 cohorts
321 IV, 12. 10 | and health~ high~Decision 1877/12/2005 National plan of
322 III, 10. 4. 2 | Commission regulation (EC) 1882/2006 lays down the sampling
323 III, 10. 4. 2 | Commission regulation (EC) 1883/2006 lays down the sampling
324 II, 5. 7. 7 | Transplant 2006 Jul;21(7):1899-905.~Meisinger C, Doring
325 IV, 12. 10 | include the following:~ ~Under 18s - A Report of the Working~
326 IV, 12. 10 | the end of life (ELV)” of 18th September 2000”~Alternative
327 II, 5. 5. 3 | epidemiologic survey. Neurology 44:1901–1907.~Brønnum-Hansen H,
328 II, 5. 2. 6 | prospective studies. Lancet 360: 1903-1913.~Kannel WB (1985).
329 II, 5. 6. 3 | with rates in men of 4 and 1909 respectively (Cooper and
330 II, 5. 2. 6 | studies. Lancet 360: 1903-1913.~Kannel WB (1985). Lipids,
331 II, 5. 8. 7 | stop-smoking rate. Chest 2003; 123: 1916-1923.~ ~Gudmundsson G, Gislason
332 II, 5. 5. 3 | project. Neurology 43(10):1918-1926.~van de Vijver DA,
333 II, 5. 8. 3 | cohort of patients born in 1919 to 1929, 1934 to 1935 and
334 II, 5. 8. 7 | rate. Chest 2003; 123: 1916-1923.~ ~Gudmundsson G, Gislason
335 II, 5. 5. 3 | project. Neurology 43(10):1918-1926.~van de Vijver DA, Roos
336 II, 5. 8. 3 | patients born in 1919 to 1929, 1934 to 1935 and 1949 to
337 II, 5. 8. 3 | patients born in 1919 to 1929, 1934 to 1935 and 1949 to 1950
338 I, 3. 3 | today’s survivors born in 1940. Some slight indentation
339 II, 6. 3. 7 | biological warfare agent since 1941.~ ~Over the last 10 years,
340 II, 5. 5. 3 | Cross-sectional~105~12.0~8.7~Alstrom, 1942 (*)~ ~NC/EC~Prevalent cohort~
341 II, 5. 5. 3 | conceptualised as ASDs.~In 1943 Leo Kanner described Infantile
342 II, 5. 8. 3 | to 1929, 1934 to 1935 and 1949 to 1950 in Northern Sweden,
343 III, 10. 6. 1 | Arch Intern Med 167(18):1951-7.~ ~Ganster DC, Victor
344 II, 5. 5. 3 | Finnish cohorts born from 1954 to 1965. Archives of General
345 II, 9. 5. 6 | Foundation: Findings Ref 1959: Characteristics of care
346 II, 9. 3. 1 | consensus.nih.gov/1992/1992Impotence091html.htm~ ~Niederlaender E (2006):
347 II, 9. 4. 5 | going to invest more than €1bn on research into new technologies
348 II, 9. 5. 3 | 20 minutes in Sweden to 1h:05 in Slovenia. Women have
349 III, 10. 2. 4 | syndrome locus on chromosome 1p36.13 and a type 2 diabetes
350 III, 10. 4. 2 | Tolerable daily intake) of 0.1µg PFOS/kg body weight (BfR
351 II, 5. 5. 3 | europarkinson.net/download/20040114EuroPa_moving_along.pdf~Eurostat (
352 III, 10. 2. 1 | 2005; Aromaa and Koskinen, 2004Direction of Health, 2004; do Carmo
353 -, 1 | Commission (Grant Agreement n. 2005115) (ii) produced through a
354 IV, 12. 10 | the Council of 15 February 2006concerning the management of bathing
355 III, 10. 2. 1 | Health Organization (WHO) (2006f) Regional Office for Europe:
356 III, 10. 1. 3 | framtidsstudier.se/filebank/files/20080109$110739$fil$mZ8UVQv2wQFShMRF6cuT.
357 III, 10. 6. 1 | InformationSources/Publications/Catalogue/20080617_1.~ ~De Vogli R, Chandola
358 III, 10. 5. 1 | et al, 2006; Zhao et al, 2008b). Recently, there has been
359 III, 10. 4. 2 | policy~Admission policy~WHO, 200a; Barlow et al.,~2002~Substances
360 II, 5. 4. 1 | hyperglycaemia 11.1 mmol/l (200mg/dl) in a random sample or
361 III, 10. 3. 1 | ranges will be completed by 2018, at an overall cost of around
362 III, 10. 4. 5 | the EU's marine waters by 2021 and to protect the resource
363 III, 10. 3. 2 | Abschlussbericht Project 20261218/03 Aktionsprogramm “Umwelt
364 II, 9. 4. 1 | will increase to 52.3 in 2028. These demographic changes
365 IV, 12. 10 | Ministerial Decision 37591/2031/2003.~In compliance with
366 II, 5. 7. 7 | Soc Nephrol 2006 Jul;17(7):2034-47.~ ~
367 IV, 12. 10 | of the Council Directive 2037/2000 concerning the substances
368 II, 5. 5. 2 | in 2020 and 81 million by 2040. These predictions are based
369 I, 3. 3 | growth rates from 2005 to 2049. Their old-age-dependency
370 III, 10. 2. 1 | Obesity (Silver Spring): 14:2054-2063.~ ~Wang Y, Lobstein
371 III, 10. 2. 1 | Silver Spring): 14:2054-2063.~ ~Wang Y, Lobstein T (2006):
372 II, 5. 8. 7 | Program. Chest 2005; 128: 2068-2075.~ ~Soriano JB, Visick
373 III, 10. 4. 2 | Commission (2005): Decision No. 2073/2005/CE of 15 November 2005
374 II, 5. 8. 7 | Program. Chest 2005; 128: 2068-2075.~ ~Soriano JB, Visick GT,
375 IV, 12. 10 | of the Council Directive 2092/91 concerning the biological
376 III, 10. 2. 1 | Nutrition Survey~ ~1997~2094~19-65~24-hour recall~1~General
377 II, 5. 8. 7 | primary care. Chest 2005; 128: 2099-2107.~ ~Soriano JB, Maier
378 II, 9. 2. 7 | 22social%20and%20cultural%20aspects%20of%20drinking%22 ] (accessed
379 IV, 12. 10 | the employer’s duty(1996)~§20b SGB V; Act on prevention
380 III, 10. 2. 1 | conferences/6gchp/hpr_050829_%20BCHP.pdf].~ ~World Health Organization (
381 II, 7. 7 | EE9D475AA6DAF58BC125747200411F14/$file/Implementation%20Council%20Recom.pdf]~ ~World Health
382 II, 9. 2. 7 | pdf#search=%22social%20and%20cultural%20aspects%20of%20drinking%
383 II, 5. 4. 8 | Definition%20and%20diagnosis%20of%20diabetes_new.pdf] (report online,
384 II, 5. 4. 8 | publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf] (
385 II, 9. 2. 7 | 20cultural%20aspects%20of%20drinking%22 ] (accessed 12.01.07)~ ~
386 II, 9. 4. 7 | healthyageing.nu/upload/pdf/Chapters%20from%20the%20report/Recommendations%
387 III, 10. 2. 1 | consume on average more than 20g alcohol per day and men
388 III, 10. 2. 1 | Lancet, 2007; 369: 2015-20Martinet Y, Bohadana A, Fagerström
389 II, 9. 4. 7 | 20report/Recommendations%20utan%20omslag.pdf].~The European Men’s
390 II, 7. 7 | Implementation%20Council%20Recom.pdf]~ ~World Health Organization (
391 II, 9. 4. 7 | pdf/Chapters%20from%20the%20report/Recommendations%20utan%20omslag.
392 II, 5. 11. 3 | occurring in housewives in their 20s and occupational hand eczema
393 II, 9. 4. 7 | upload/pdf/Chapters%20from%20the%20report/Recommendations%
394 II, 9. 4. 7 | 20report/Recommendations%20utan%20omslag.pdf].~The European
395 III, 10. 5. 1 | classroom temperature from 25 to 20°C increased speed at different
396 II, 5. 9. FB | Children (ALSPAC), performed on 2100 British children, reported
397 II, 5. 8. 7 | care. Chest 2005; 128: 2099-2107.~ ~Soriano JB, Maier WC,
398 III, 10. 2. 4 | metabolic syndrome. Obes Res, 13:2122-2131.~ ~Torhorst J, Bucher
399 II, 9. 3. 3 | health and rights (2001/2128 (INI)). Official Journal
400 III, 10. 2. 4 | syndrome. Obes Res, 13:2122-2131.~ ~Torhorst J, Bucher C,
401 II, 5. 7. 7 | Soc Nephrol 2005 Jul;16(7):2134-40.~Levey AS, Bosch JP,
402 II, 5. 4. 3 | between 21 (Cyprus) and 2135 (Austria), with a median
403 II, 8. 2. 1 | of children (altogether 21397 individuals) in Northern
404 II, 5. 4. 8 | retrieveFile?instanceid=9&itemid=2140&style=home]~(report online,
405 II, 5. 5. 3 | Study. Neurology 45(12):2143-2146.~de Rijk MC, Tzourio
406 III, 10. 4. 3 | standards. Science 296: 2145-2146.~The United Nations
407 IV, 12. 10 | o Ministerial Decision 21475/4707 (published in 1998)
408 III, 10. 3. 2 | industrial chemicals. Lancet 368, 2167-2178.~ ~Westfälisches Institut
409 III, 10. 2. 1 | EC): No 2200/96, (EC): No 2201/96, (EC): No 2826/2000, (
410 III, 10. 2. 1 | repealing Regulation (EC): No 2202/96.~[http://eur-lex.europa.
411 II, 9. 5. 6 | 2005 (Vol. 61) (No. 10) 2221-2232~Heinrich G A (2000):
412 II, 5. 5. 3 | disease. Neurology 43(11):2227-2229.~Gorell JM, Rybicki
413 II, 5. 5. 3 | disease. Neurology 43(11):2227-2229.~Gorell JM, Rybicki BA,
414 II, 9. 5. 6 | Vol. 61) (No. 10) 2221-2232~Heinrich G A (2000): Affluence
415 III, 10. 4. 2 | Commission Regulation (EC) No 2245/2003 and Commission Regulation (
416 III, 10. 2. 4 | endpoints. Am J Pathol, 159:2249-2256.~ ~UNESCO (1997): Universal
417 III, 10. 2. 4 | endpoints. Am J Pathol, 159:2249-2256.~ ~UNESCO (1997): Universal
418 II, 9. 3. 1 | 2007:2) ISBN 978-952-00-2269-3 (paperback) ISBN 978-952-
419 II, 9. 3. 1 | paperback) ISBN 978-952-00-2270-9 (PDF)~ ~Mental Health
420 II, 5. 7. 7 | Am Soc Nephrol 2006; 17:2275-84.~Hallan SI, Dahl K, Oien
421 III, 10. 5. 2 | www.biomedcentral.com/1471-2296/6/16] (accessed on 19 September
422 II, 5. 5. 3 | community-based study. Brain 123:2297-2305.~Singer E (1973): Social
423 II, 9. 2. 7 | social_drinking.pdf#search=%22social%20and%20cultural%20aspects%
424 II, 5. 5. 3 | community-based study. Brain 123:2297-2305.~Singer E (1973): Social
425 III, 10. 5. 2 | in New Zealand (based on 232 studies / papers etc.) came
426 II, 5. 2. 7 | stroke project. Stroke 33:2367-2375.~Tunstall-Pedoe H,
427 II, 9. 3. 1 | Internal Medicine, 166: 2395 – 2402. Cited by Cancer
428 III, 10. 4. 2 | With regard to Article 23f and 34 of Regulation (EC)
429 II, 5. 5. 3 | Poster presentation at 23rd European Congress for the
430 II, 9. 3. 1 | Internal Medicine, 166: 2395 – 2402. Cited by Cancer Help UK (htt ~ ~
431 II, 5. 5. 3 | focus. Acta Neurol Scand 88:241-246.~Grytten N, Glad SB,
432 II, 5. 4. 8 | Ugeskr Laeger. 18;169(25):2432-4 [Article in Danish]~EUCID
433 IV, 12. 10 | limits of poverty.~o Law 2434/1996 established the Benefit
434 II, 5. 5. 3 | Teruel, Spain. J Neurol 244:182-185.~Mor u T, eaManceau
435 IV, 12. 10 | Common Ministerial Decision 245090/11.1.2006 for determining
436 II, 5. 9. 7 | Suppl 1):S2 doi:10.1186/1471-2466-6-S1-S2).~ ~Jarvis D, Luczynska
437 II, 5. 5. 3 | comparison Br J Psychiatry 187: 248-255.~Glynn SM (2003): Psychiatric
438 II, 9. 5. 6 | Biomarkers Prev. 2006 Dec;15(12):2494-501~ ~Middle C, Johnson
439 II, 5. 8. 3 | present in 10.4% of the 2497 subjects with different
440 II, 5. 7. 2 | ERA-EDTA (Barcelona, 21st - 24th June 2007) (Zoccali and
441 II, 5. 9. 3 | 44900 had asthma diagnosis, 25100 received treatment from
442 II, 5. 5. 3 | ECA) Study. JAMA 264 (19):2511-2518.~Saha S, Chant D, McGrath
443 II, 5. 5. 3 | Study. JAMA 264 (19):2511-2518.~Saha S, Chant D, McGrath
444 III, 10. 2. 1 | Science and Medicine, 58: 2523-35.~ ~Ditter SM, Elder RW,
445 IV, 12. 10 | for Pensioners (EKAS); law 2556/1997 enlarged the group
446 II, 5. 7. 7 | the JNC 7 report. JAMA 19):2560-72.~Cirillo M, Laurenzi
447 II, 5. 7. 7 | Nephrol 2003 Oct;14(10):2573-80.~Loucks EB, Rehkopf DH,
448 II, 9. 5. 6 | health. Soc Sci Med 58(12):2585-2600~ ~De Smedt M, (2004):
449 II, 5. 2. 5 | European Union - 950/04 – 2586 Council Meeting – 1 and
450 III, 10. 4. 2 | public consultation closed on 25th March.~ ~· Fate of pesticides (
451 II, 9. 5. 6 | Soc Sci Med 58(12):2585-2600~ ~De Smedt M, (2004): Towards
452 II, 7. 4. 1 | age group is estimated as 26000 cases in the EU27. For every
453 II, 5. 8. 3 | Masa et al, 2004) and 1 261€ in Italy.~ ~An analysis
454 III, 10. 5. 2 | org/document/61/0,3343,en_2649_37429_38690301_1_1_1_37429,
455 III, 10. 2. 1 | among adults~NORKOST~1997~2672~16-79~Food Frequency Questionnaire~ ~ ~
456 IV, 12. 10 | eligible pensioners, while law 2676/1999 increased the amount
457 IV, 12. 10 | comparison with the previous code 2696/1999) makes stricter the
458 II, 5. 7. 5 | chronic diseases. On September 26th 2007, after a special convention
459 IV, 12. 10 | in Greece with the law N. 2716/99 and the national program
460 IV, 12. 10 | Ministerial Decision 50910/2727/2003 “Measures and terms
461 II, 5. 4. 8 | prevention of type 2 diabetes, 2733rd Employment, Social Policy,
462 III, 10. 1. 3 | Research. Circulation 114:2739-2752.~Marshall JR (1994):
463 III, 10. 1. 3 | Research. Circulation 114:2739-2752.~Marshall JR (1994): The
464 II, 5. 6. 3 | among all respondents (n=2755) in Sweden~ ~ ~Figure 5.
465 II, 5. 7. 7 | Kidney Int 2005 Dec;68(6):2801-8.~Hallan SI, Coresh J,
466 II, 5. 2. 6 | Trial (MRFIT). JAMA 256: 2823-2828.~Turnbull F; Blood
467 III, 10. 2. 1 | EC): No 2201/96, (EC): No 2826/2000, (EC): No 1782/2003
468 II, 5. 2. 6 | MRFIT). JAMA 256: 2823-2828.~Turnbull F; Blood Pressure
469 III, 10. 2. 5 | factors. Diabetologia 2006;49:2853 - 8~ ~Gale CR, Martyn CN (
470 III, 10. 1. 3 | Alcohol Clin Exp Res 22(7):285S-298S.~Thompson JC (2005): The
471 II, 5. 11. 3 | Contact Dermatitis,1985;13:289–293.~C Lidén, M Bruze, T
472 II, 5. 4. 8 | and its morbidity HMP SI2.2895.39~Gudbjörnsdottir S, Cederholm
473 III, 10. 4. 2 | food supplements.~ ~On 28th January 2002 the European
474 IV, 12. 10 | Common Ministerial Decision 29407/3508/2002 in compliance
475 II, 5. 5. 3 | Pharmacoeconomics 14(3):299-312.~Dorsey ER, Constantinescu
476 II, 5. 3. 6 | al, 2003).~ ~Figure 5.3.29a. All cancers (ICD9 140-172,
477 II, 5. 3. 6 | December 1999 A) Men~Figure 5.3.29b. All cancers (ICD9 140-172,
478 III, 10. 4. 2 | and distribution.~ ~On the 29th April 2004, Regulation EC
479 II, 9. 1. 2 | Sante Publique, Vol 53, pp 2S87-2S95.~Dolk H, Vrijheid, Scott
480 II, 5. 5. 3(26)| A5-0451/3003 European Parliament Resolution
481 III, 10. 2. 1 | Scandinavian countries, 300µg/d of folate are recommended
482 IV, 12. 1 | fundamental freedoms’.~ ~Art. 300-302 (Closing of agreements with
483 III, 10. 4. 2 | 823 in 2000, 1567 in 2001, 3024 in 2002, 4414 in 2003, 5562
484 II, 5. 6. 3 | aged under 35,rising to 3032/100,000 person-years in
485 IV, 12. 10 | High~ Ministerial Decision 30528/ (23.3.2005) concerning
486 II, 5. 3. 6 | al, 2003).~ ~Figure 5.3.30a. Stomach cancer (ICD9 151)
487 II, 5. 3. 6 | December 1999 A) Men~Figure 5.3.30b. Stomach cancer (ICD9 151)
488 II, 5. 2. 4 | obesity (defined as BMI 30kg/m2 ) in 27 EU countries
489 II, 8. 1. 5 | European Commission adopted on 30th of October 2003 a Communication
490 II, 5. 10. 7 | of the European Union L 310, 28.11.2007, pp. 11–14.~ ~
491 II, 5. 7. 7 | analysis. JAMA 2003;290(23):3101-14.~Chadban SJ, Briganti
492 III, 10. 4. 2(27)| Document No SANCO/2007/3131,31/10/2007.~
493 II, 5. 3. 6 | al, 2003).~ ~Figure 5.3.31a. Colorectal cancer (ICD9
494 II, 5. 3. 6 | December 1999 A) Men~Figure 5.3.31b. Colorectal cancer (ICD9
495 III, 10. 2. 1 | LexUriServ.do?uri=CELEX:32000L0013:EN:HTML].~European Council (
496 III, 10. 2. 1 | LexUriServ.do?uri=CELEX:32001L0015:EN:HTML]~ ~European Commission (
497 II, 7. 7 | product safety (CELEX-Nr. 32001L0095).~ ~EuroSafe (2008): Injuries
498 III, 10. 2. 1 | LexUriServ.do?uri=CELEX:32002L0046:EN:HTML]~European Council (
499 II, 7. 7 | July 18, 2007 (CELEX-Nr. 32007H0718).~ ~European Commission (
500 IV, 12. 10 | 655 respectively.~o Law 3227/2004 Concerning the duties
